Open AccessBudesonide (Jorveza)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.131
Subject(s) - eosinophilic esophagitis , dysphagia , medicine , budesonide , swallowing , proton pump inhibitor , pediatrics , intensive care medicine , asthma , physical therapy , surgery , disease
CADTH recommends that Jorveza should be reimbursed by public drug plans for the maintenance of remission in adults with eosinophilic esophagitis (EoE) if certain conditions are met.
Jorveza should only be reimbursed if prescribed by a specialist with experience in the diagnosis and management of EoE, and the cost of Jorveza is reduced.
Jorveza should only be covered for adult patients who have a confirmed diagnosis of EoE, in whom treatment with a proton pump inhibitor (PPI) did not work, and whose symptoms (dysphagia and pain during swallowing) have resolved after receiving induction treatment with Jorveza.